129 related articles for article (PubMed ID: 19223422)
1. Identification and characterization of a peptide with affinity to head and neck cancer.
Nothelfer EM; Zitzmann-Kolbe S; Garcia-Boy R; Krämer S; Herold-Mende C; Altmann A; Eisenhut M; Mier W; Haberkorn U
J Nucl Med; 2009 Mar; 50(3):426-34. PubMed ID: 19223422
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
3. Identification and evaluation of a new tumor cell-binding peptide, FROP-1.
Zitzmann S; Krämer S; Mier W; Hebling U; Altmann A; Rother A; Berndorff D; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Jun; 48(6):965-72. PubMed ID: 17504878
[TBL] [Abstract][Full Text] [Related]
4. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
5. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel ITGα
Altmann A; Sauter M; Roesch S; Mier W; Warta R; Debus J; Dyckhoff G; Herold-Mende C; Haberkorn U
Clin Cancer Res; 2017 Aug; 23(15):4170-4180. PubMed ID: 28468949
[No Abstract] [Full Text] [Related]
7. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
9. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
[TBL] [Abstract][Full Text] [Related]
10. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
11. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
12. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
13. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
[TBL] [Abstract][Full Text] [Related]
14. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Sandström K; Haylock AK; Velikyan I; Spiegelberg D; Kareem H; Tolmachev V; Lundqvist H; Nestor M
Cancer Biother Radiopharm; 2011 Oct; 26(5):593-601. PubMed ID: 21834651
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
[TBL] [Abstract][Full Text] [Related]
16. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
17. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
18. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
19. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
Li ZB; Wu Z; Chen K; Ryu EK; Chen X
J Nucl Med; 2008 Mar; 49(3):453-61. PubMed ID: 18287274
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs.
Lee KH; Jung KH; Song SH; Kim DH; Lee BC; Sung HJ; Han YM; Choe YS; Chi DY; Kim BT
J Nucl Med; 2005 Mar; 46(3):472-8. PubMed ID: 15750161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
